Eylea 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Eylea
Active substance
aflibercept
Therapeutic area (MeSH)
  • Wet Macular Degeneration
  • Macular Edema
  • Diabetes Complications
Procedure number
EMEA/H/C/002392/II/0068
Regulatory outcome
Variation
DHPC type
Adverse event
Human ATC code
S01LA05
Dissemination date
15/04/2021

How useful was this page?

Add your rating